IN2014KN01713A - - Google Patents

Info

Publication number
IN2014KN01713A
IN2014KN01713A IN1713KON2014A IN2014KN01713A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A IN 1713KON2014 A IN1713KON2014 A IN 1713KON2014A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01713A publication Critical patent/IN2014KN01713A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1713KON2014 2012-02-21 2013-02-21 IN2014KN01713A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014KN01713A true IN2014KN01713A (cs) 2015-10-23

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1713KON2014 IN2014KN01713A (cs) 2012-02-21 2013-02-21

Country Status (16)

Country Link
US (1) US9273130B2 (cs)
EP (1) EP2818482B1 (cs)
JP (1) JP6187255B2 (cs)
KR (1) KR102009238B1 (cs)
CN (1) CN104169303B (cs)
AU (1) AU2013223143B2 (cs)
CA (1) CA2864864C (cs)
DK (1) DK2818482T3 (cs)
ES (1) ES2739612T3 (cs)
HU (1) HUE044611T2 (cs)
IN (1) IN2014KN01713A (cs)
MX (1) MX360208B (cs)
PL (1) PL2818482T3 (cs)
PT (1) PT2818482T (cs)
RU (1) RU2632645C2 (cs)
WO (1) WO2013125636A1 (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
MX340015B (es) * 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2844037C (en) * 2011-08-04 2020-07-14 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR101984554B1 (ko) * 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
JP6187256B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
BR112014024209A2 (pt) 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
KR102056137B1 (ko) 2012-07-19 2019-12-16 도레이 카부시키가이샤 암의 검출 방법
TR201902972T4 (tr) 2012-07-19 2019-03-21 Toray Industries Kanseri tespit etmek için yöntem.
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
HUE042081T2 (hu) 2013-08-09 2019-06-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
KR102355950B1 (ko) 2016-03-04 2022-01-26 제이엔 바이오사이언시즈 엘엘씨 Tigit에 대한 항체
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
MX2019004779A (es) 2016-10-28 2019-08-12 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20200136935A (ko) 2018-03-30 2020-12-08 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Her2を標的とする免疫結合体
CA3142887A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11654199B2 (en) 2019-10-25 2023-05-23 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
CA3175129A1 (en) 2020-03-12 2021-09-19 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230159635A1 (en) 2020-03-12 2023-05-25 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175127A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
JPWO2021182570A1 (cs) 2020-03-12 2021-09-16
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ-基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
IL300316A (en) 2020-08-13 2023-04-01 Bolt Biotherapeutics Inc Immune conjugates of pyrazolozapines and their uses
BR112023026985A2 (pt) 2021-06-23 2024-03-12 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CA3227703A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023008459A1 (cs) 2021-07-27 2023-02-02
JPWO2023033129A1 (cs) 2021-09-03 2023-03-09
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
EP4548932A1 (en) 2022-06-30 2025-05-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JPWO2024043257A1 (cs) 2022-08-24 2024-02-29
KR20250052369A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024043258A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
EP4582100A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN120302998A (zh) 2022-12-23 2025-07-11 东丽株式会社 用于癌的治疗和/或预防的药品
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
PL200772B1 (pl) 1998-07-14 2009-02-27 Corixa Corp Izolowany polipeptyd, fuzja białkowa oraz ich zastosowanie, izolowany epitop komórki T, wektor ekspresyjny, komórka gospodarza, sposób stymulowania i/lub namnażania komórek T, izolowana populacja komórek T, kompozycja i jej zastosowanie oraz izolowane komórki T
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU1438001A (en) 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CZ20023567A3 (cs) 2000-03-29 2003-11-12 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
KR100770065B1 (ko) 2001-05-11 2007-10-24 기린 파마 가부시끼가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
AU2003302386B2 (en) 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
JP2008506352A (ja) 2004-01-26 2008-03-06 デビオビジョン・インコーポレーテッド 新生物特異的ポリペプチド及びその使用
EP2332990A1 (en) 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
SG151292A1 (en) 2004-03-30 2009-04-30 Glaxo Group Ltd Immunoglobulins
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
KR20150083139A (ko) 2005-01-21 2015-07-16 제넨테크, 인크. Her 항체의 고정 용량 투여법
CN101120252A (zh) 2005-02-18 2008-02-06 儿童医疗中心有限公司 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
EP2207037B1 (en) 2007-10-25 2016-09-07 Toray Industries, Inc. Method for detection of cancer
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
BRPI0906181A2 (pt) 2008-03-18 2015-06-30 Genentech Inc "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
ES2525551T3 (es) * 2008-07-31 2014-12-26 Senomyx, Inc. Composiciones que comprenden potenciadores de dulzor y métodos de producirlas
CN103751771B (zh) 2008-08-05 2017-09-08 东丽株式会社 免疫诱导剂
PT2322221E (pt) * 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
DK2733492T3 (en) * 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
ES2622487T3 (es) 2009-08-19 2017-07-06 Merck Patent Gmbh Anticuerpos para la detección de complejos de integrina en material FFPE
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
US9180187B2 (en) 2010-02-04 2015-11-10 Toray Industries, Inc. Medicament for treating and/or preventing cancer
PT2532365T (pt) * 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
MX340017B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2011211682B2 (en) * 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532366T3 (pl) 2010-02-04 2017-02-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
EA201790882A1 (ru) 2010-07-26 2017-08-31 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
JP2012035484A (ja) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd 塗膜転写具
KR101984554B1 (ko) 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
CA2844037C (en) 2011-08-04 2020-07-14 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
BR112014002608A2 (pt) 2011-08-04 2018-02-20 Toray Industries anticorpo ou seu fragmento que possui reatividade imunológica com um polipeptídeo caprin-1, composição farmacêutica e combinação farmacêutica de tratamento e/ou prevenção de câncer, dna e método de tratamento e/ou prevenção de câncer
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
BR112014024209A2 (pt) * 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar

Also Published As

Publication number Publication date
CN104169303A (zh) 2014-11-26
AU2013223143B2 (en) 2017-12-21
EP2818482B1 (en) 2019-05-22
EP2818482A1 (en) 2014-12-31
DK2818482T3 (da) 2019-07-15
MX2014009748A (es) 2014-11-14
PT2818482T (pt) 2019-08-06
EP2818482A4 (en) 2015-10-07
MX360208B (es) 2018-10-24
JPWO2013125636A1 (ja) 2015-07-30
BR112014021101A2 (pt) 2022-03-22
KR102009238B1 (ko) 2019-08-09
KR20140130668A (ko) 2014-11-11
HUE044611T2 (hu) 2019-11-28
JP6187255B2 (ja) 2017-08-30
PL2818482T3 (pl) 2019-11-29
WO2013125636A1 (ja) 2013-08-29
RU2632645C2 (ru) 2017-10-06
CA2864864A1 (en) 2013-08-29
ES2739612T3 (es) 2020-02-03
CA2864864C (en) 2020-05-12
US20150004171A1 (en) 2015-01-01
AU2013223143A1 (en) 2014-09-11
CN104169303B (zh) 2018-05-29
US9273130B2 (en) 2016-03-01
RU2014138040A (ru) 2016-04-10

Similar Documents

Publication Publication Date Title
IN2014KN01713A (cs)
IN2014KN01714A (cs)
IN2014KN01716A (cs)
IN2014KN01715A (cs)
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
NZ705370A (en) Fcγriib-specific fc region variant
MY167232A (en) Polypeptides binding to human complement c5
IN2014DN09963A (cs)
MX369195B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
GB201118201D0 (en) Novel peptides
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2014039074A3 (en) Therapeutic compositions and related methods
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.